PHILADELPHIA (GenomeWeb) – At the American Association for Clinical Chemistry annual meeting here today, BioRad Laboratories announced that it has received 510(k)clearance from the US Food and Drug Administration for a multi-analyte quality control designed to monitor the performance of in vitro nucleic acid tests for viral load assays used in the diagnosis of human immunodeficiency type 1, hepatitis B, and hepatitis C viruses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.